Yale YODA Project announces first availability of medical device trial data

January 14, 2015, Yale University
Credit: Shutterstock/Yale University

The Yale University Open Data Access (YODA) Project is announcing the first-ever broad availability of clinical trial data for medical devices and diagnostics by a company. This historic expansion of data sharing is made possible through collaboration with Johnson & Johnson.

In this groundbreaking move, results from the clinical trails of the Medical Devices and Diagnostics businesses of Johnson & Johnson will be made available to researchers through an agreement with the Yale YODA Project. This establishes a fully independent intermediary to manage requests and promote data use, just as it has done with its pharmaceutical .

The YODA Project will continue to act as a bridge between investigators and Johnson & Johnson's pharmaceutical and device and diagnostics businesses. Under the arrangement, the YODA Project will approve or deny requests from investigators for de-identified patient data associated with the pharmaceutical, medical device, and diagnostic conducted by Johnson & Johnson companies. This expanded scope that now includes device and diagnostic studies is another step forward in the continuing evolution of open science in clinical medicine.

"This action will benefit society and represents a major step forward in the effort to promote , as Johnson & Johnson's leadership in this area now extends from sharing its drug data to sharing its device and diagnostics data," said Dr. Harlan Krumholz, professor of medicine and leader of the YODA Project. "We hope this action serves as a catalyst to others to join the momentum on open science."

Dr. Joseph Ross, associate professor of medicine and member of the YODA Project, added, "Data sharing maximizes knowledge generation from clinical research studies, enabling multiple investigators to use the data for additional research projects. Through sharing of clinical trial data for , we can now learn more about these important medical treatments."

Dr. Joanne Waldstreicher, chief medial officer of Johnson & Johnson said, "Sharing data from clinical trials leads to greater insights in medicine. This agreement with the YODA Project underscores Johnson & Johnson's commitment to responsibly share clinical trial data with researchers in a way that we believe advances medical science and public health."

Requests for data may be directly submitted to the YODA Project through its website.

Explore further: Safety review of bone growth product ushers in new era of data sharing

Related Stories

Safety review of bone growth product ushers in new era of data sharing

June 17, 2013
A Yale project involving the independent review of a bone growth product's safety has yielded results, which are published in the June 18 issue of Annals of Internal Medicine. The findings are part of the Yale University ...

Data sharing in pharmaceutical industry shows progress

October 16, 2014
To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Johnson & Johnson plans Ebola vaccine testing

October 22, 2014
Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.

Johnson & Johnson buying Alios for $1.75B

September 30, 2014
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion.

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.